Fairman Group
BIIB icon

Fairman Group’s Biogen BIIB Stock Holding History

Fairman Group’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$678 Hold
3
– – ﹤0.01% 308
2026
Q2 		$648 Hold
3
– – ﹤0.01% 309
2026
Q1 		$550 Hold
3
– – ﹤0.01% 303
2025
Q4 		$528 Sell
3
-3
-50% -$490 ﹤0.01% 312
2025
Q3 		$840 Hold
6
– – ﹤0.01% 246
2025
Q2 		$754 Hold
6
– – ﹤0.01% 229
2025
Q1 		$918 Hold
6
– – ﹤0.01% 222
2024
Q4 		$918 Hold
6
– – ﹤0.01% 284
2024
Q3 		$1.16K Hold
6
– – ﹤0.01% 327
2024
Q2 		$1.39K Hold
6
– – ﹤0.01% 305
2024
Q1 		$1.29K Hold
6
– – ﹤0.01% 312
2023
Q4 		$1.55K Buy
+6
New +$1.47K ﹤0.01% 287

Other funds holding BIIB

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Artemis Investment Management
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
B. Metzler seel. Sohn & Co
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.5B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Fairman Group's BIIB Position: Q3 2026 in Review

Fairman Group held its Biogen (BIIB) position steady in Q3 2026 at 3 shares worth $678. The position accounts for ﹤0.01% of the portfolio, ranked #308.

Fairman Group first reported a position in BIIB in Q4 2023 and has held it in 12 quarters since. The position peaked at $1.55K in Q4 2023. 461 funds tracked by Wall St. Rank hold BIIB as of Q3 2026.

  • Fairman Group held 3 shares of Biogen worth $678 as of Q3 2026.
  • Fairman Group left its Biogen share count unchanged in Q3 2026.
  • Biogen made up ﹤0.01% of Fairman Group's portfolio in Q3 2026, its #308 holding.
  • Fairman Group first reported a position in Biogen in Q4 2023 and has held it in 12 quarters since.
  • Fairman Group's Biogen position peaked at $1.55K in Q4 2023.
  • 461 funds tracked by Wall St. Rank held Biogen as of Q3 2026.

Based on Fairman Group's 13F filing for Q3 2026, filed 26 Oct 2026.